|Awarded On||November 16, 2016|
|Title||OCT4/c-MYC axis as a mechanism of resistance to 13-cis retinoic acid in neuroblastoma|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||Texas Tech University Health Sciences Center|
|Principal Investigator/Program Director||Min H Kang|
|Cancer Sites||Brain and Other Nervous System|
A drug derived from vitamin A called isotretinoin is being used to treat the pediatric cancer neuroblastoma. Although the drug can cause cancer cells to change to non-growing, non-cancerous cells, such a response requires high drug levels. Some patients have low levels of drug, perhaps because of how it is given to young children, and perhaps because of genetic factors of patients. During the current study, we found that patients who are older than 18 months of age survive longer if the levels of the drug and the drug break-down product are higher. Our study is the largest study showing the actual relationship between the drug levels and the survival of patients in neuroblastoma. While we w...